Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy

Yagi,Shigetaka; Yahata,Tamaki; Mabuchi,Yasushi; Tanizaki,Yuko; Kobayashi,Aya; Shiro,Michihisa; Ota,Nami; Minami,Sawako; Terada,Masaki; Ino,Kazuhiko

doi:10.3892/mco.2016.953

Primary tumor SUVmax on preoperative FDG-PET/CT is a prognostic indicator in stage IA2-IIB cervical cancer patients treated with radical hysterectomy

Authors:
- Shigetaka Yagi
- Tamaki Yahata
- Yasushi Mabuchi
- Yuko Tanizaki
- Aya Kobayashi
- Michihisa Shiro
- Nami Ota
- Sawako Minami
- Masaki Terada
- Kazuhiko Ino
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Wakayama Medical University, Wakayama 641‑0012, Japan, Wakayama Minami Radiology Clinic, Wakayama 641‑0012, Japan
Published online on: July 7, 2016 https://doi.org/10.3892/mco.2016.953
Pages: 216-222

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The objective of the present study was to investigate the prognostic value of 18F-fluoro-2-deoxy-D-glucose (FDG) uptake by primary tumors on positron emission tomography/computed tomography (PET/CT) in surgically resectable cervical cancer. A total of 59 patients with stage IA2‑IIB cervical cancer who underwent preoperative FDG‑PET/CT, followed by radical hysterectomy and lymphadenectomy, were included in the study. The maximum standardized uptake value (SUVmax) of the primary tumor was measured, and the association between the SUVmax and clinicopathological factors or patient outcomes was analyzed. The SUVmax was significantly higher in patients with an advanced stage, lymph node metastasis, lymph‑vascular space involvement and large tumors. The overall survival (OS) and progression‑free survival (PFS) of patients with a high SUVmax were significantly lower compared with patients with a low SUVmax, using an optimal cut‑off value of 7.36 for OS and 5.59 for PFS obtained from receiver operating characteristic curve analysis. Similarly, OS and PFS in patients with a high SUVmax were significantly lower in 39 patients with stage IB using a cut‑off value of 7.90 and 6.69 for OS and PFS, respectively. Finally, multivariate analyses showed that the SUVmax of the primary tumor was an independent prognostic factor for impaired PFS in all patients and those with stage IB alone. These findings demonstrated that a high SUVmax on preoperative PET/CT was correlated with unfavorable clinical outcomes in patients receiving radical hysterectomy, suggesting that the SUVmax of the primary tumor may be a prognostic indicator for surgically‑treated, early-stage invasive cervical cancer.

View Figures

View References

1	Kesic V: Management of cervical cancer. Eur J Surg Oncol. 32:832–837. 2006. View Article : Google Scholar : PubMed/NCBI
2	Monk BJ, Tewari KS and Koh WJ: Multimodality therapy for locally advanced cervical carcinoma: State of the art and future directions. J Clin Oncol. 25:2952–2965. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yamagami W and Aoki D: Annual report of the committee on gynecologic oncology, the Japan society of obstetrics and gynecology. J Obstet Gynaecol Res. 41:1861–1869. 2015. View Article : Google Scholar : PubMed/NCBI
4	Takekuma M, Kasamatsu Y, Kado N, Kuji S, Tanaka A, Takahashi N, Abe M and Hirashima Y: Reconsideration of postoperative concurrent chemoradiotherapy with fluorouracil and cisplatin for uterine cervical cancer. J Obstet Gynaecol Res. 41:1638–1643. 2015. View Article : Google Scholar : PubMed/NCBI
5	Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, Oikawa M, Yamamoto R, Yamada H and Fujimoto S: Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. Acta Obstet Gynecol Scand. 81:1144–1151. 2002. View Article : Google Scholar : PubMed/NCBI
6	Singh N and Arif S: Histopathologic parameters of prognosis in cervical cancer-a review. Int J Gynecol Cancer. 14:741–750. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y and Tsuda H: Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix. Br J Cancer. 100:1400–1405. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mabuchi Y, Yahata T, Kobayashi A, Tanizaki Y, Shiro M, Ota N, Yagi S, Minami S and Ino K: Clinicopathologic factors of cervical adenocarcinoma stages IB to IIB. Int J Gynecol Cancer. 25:1677–1682. 2015. View Article : Google Scholar : PubMed/NCBI
9	Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR and Stein AT: Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database Syst Rev. 6:CD0053422012.PubMed/NCBI
10	Ryu HS, Chun M, Chang KH, Chang HJ and Lee JP: Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecol Oncol. 96:490–495. 2005. View Article : Google Scholar : PubMed/NCBI
11	Kitajima K, Suzuki K, Senda M, Kita M, Nakamoto Y, Onishi Y, Maeda T, Yoshikawa T, Ohno Y and Sugimura K: FDG-PET/CT for diagnosis of primary ovarian cancer. Nucl Med Commun. 32:549–553. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tanizaki Y, Kobayashi A, Shiro M, Ota N, Takano R, Mabuchi Y, Yagi S, Minami S, Terada M and Ino K: Diagnostic value of preoperative SUV_max on FDG-PET/CT for the detection of ovarian cancer. Int J Gynecol Cancer. 24:454–460. 2014. View Article : Google Scholar : PubMed/NCBI
13	Kitajima K, Kita M, Suzuki K, Senda M, Nakamoto Y and Sugimura K: Prognostic significance of SUV_max (maximum standardized uptake value) measured by [18F]FDG PET/CT in endometrial cancer. Eur J Nucl Med Mol Imaging. 39:840–845. 2012. View Article : Google Scholar : PubMed/NCBI
14	Antonsen SL, Loft A, Fisker R, Nielsen AL, Andersen ES, Høgdall E, Tabor A, Jochumsen K, Fagö-Olsen CL, Asmussen J, et al: SUV_max of ¹⁸FDG PET/CT as a predictor of high-risk endometrial cancer patients. Gynecol Oncol. 129:298–303. 2013. View Article : Google Scholar : PubMed/NCBI
15	Nakamura K, Hongo A, Kodama J and Hiramatsu Y: The measurement of SUV_max of the primary tumor is predictive of prognosis for patients with endometrial cancer. Gynecol Oncol. 123:82–87. 2011. View Article : Google Scholar : PubMed/NCBI
16	Gouy S, Morice P, Narducci F, Uzan C, Gilmore J, Kolesnikov-Gauthier H, Querleu D, Haie-Meder C and Leblanc E: Nodal-staging surgery for locally advanced cervical cancer in the era of PET. Lancet Oncol. 13:e212–e220. 2012. View Article : Google Scholar : PubMed/NCBI
17	Kidd EA, Siegel BA, Dehdashti F, Rader JS, Mutch DG, Powell MA and Grigsby PW: Lymph node staging by positron emission tomography in cervical cancer: Relationship to prognosis. J Clin Oncol. 28:2108–2113. 2010. View Article : Google Scholar : PubMed/NCBI
18	Kidd EA, Siegel BA, Dehdashti F and Grigsby PW: The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 110:1738–1744. 2007. View Article : Google Scholar : PubMed/NCBI
19	Lee YY, Choi CH, Kim CJ, Kang H, Kim TJ, Lee JW, Lee JH, Bae DS and Kim BG: The prognostic significance of the SUV_max (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary results. Gynecol Oncol. 115:65–68. 2009. View Article : Google Scholar : PubMed/NCBI
20	Cho SH, Lim JY, Kim SN, Hong S, Chung HW, So Y, Kim WY and Lee SJ: The prognostic significance of pretreatment [18F]FDG-PET/CT imaging in patients with uterine cervical cancer: Preliminary results. Eur J Gynaecol Oncol. 36:30–35. 2015.PubMed/NCBI
21	Crivellaro C, Signorelli M, Guerra L, De Ponti E, Buda A, Dolci C, Pirovano C, Todde S, Fruscio R and Messa C: ¹⁸F-FDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol. 127:131–135. 2012. View Article : Google Scholar : PubMed/NCBI
22	Kim BS, Kim IJ, Kim SJ, Nam HY, Pak KJ, Kim K and Yun MS: The prognostic value of the metabolic tumor volume in FIGO stage IA to IIB cervical cancer for tumor recurrence: Measured by F-18 FDG PET/CT. Nucl Med Mol Imaging. 45:36–42. 2011. View Article : Google Scholar : PubMed/NCBI
23	Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA and Grigsby PW: F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol Oncol. 101:147–151. 2006. View Article : Google Scholar : PubMed/NCBI
24	Yun MS, Kim SJ, Pak K and Lee CH: Additional prognostic value of SUV_max measured by F-18 FDG PET/CT over biological marker expressions in surgically resected cervical cancer patients. Oncol Res Treat. 38:413–416. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kitajima K, Suenaga Y, Ueno Y, Maeda T, Ebina Y, Yamada H, Okunaga T, Kubo K, Sofue K, Kanda T, et al: Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer. Eur J Nucl Med Mol Imaging. 42:1268–1275. 2015. View Article : Google Scholar : PubMed/NCBI
26	Chung HH, Kim JW, Han KH, Eo JS, Kang KW, Park NH, Song YS, Chung JK and Kang SB: Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer. Gynecol Oncol. 120:270–274. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yoo J, Choi JY, Moon SH, Bae DS, Park SB, Choe YS, Lee KH and Kim BT: Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using ¹⁸F-fluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer. 22:1226–1233. 2012. View Article : Google Scholar : PubMed/NCBI
28	Kidd EA and Grigsby PW: Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res. 14:5236–5241. 2008. View Article : Google Scholar : PubMed/NCBI
29	Tong SY, Lee JM, Ki KD, Choi YJ, Seol HJ, Lee SK, Huh CY, Kim GY and Lim SJ: Correlation between FDG uptake by PET/CT and the expressions of glucose transporter type 1 and hexokinase II in cervical cancer. Int J Gynecol Cancer. 22:654–658. 2012. View Article : Google Scholar : PubMed/NCBI
30	Park SI, Suh DS, Kim SJ, Choi KU and Yoon MS: Correlation between biological marker expression and F-fluorodeoxyglucose uptake in cervical cancer measured by positron emission tomography. Onkologie. 36:169–174. 2013. View Article : Google Scholar : PubMed/NCBI
31	Nakamura K, Okumura Y, Kodama J, Hongo A, Kanazawa S and Hiramatsu Y: The predictive value of measurement of SUV_max and SCC-antigen in patients with pretreatment of primary squamous cell carcinoma of cervix. Gynecol Oncol. 119:81–86. 2010. View Article : Google Scholar : PubMed/NCBI
32	Pan L, Cheng J, Zhou M, Yao Z and Zhang Y: The SUV_max (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer. J Cancer Res Clin Oncol. 138:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
33	Miccò M, Vargas HA, Burger IA, Kollmeier MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H and Sala E: Combined pre-treatment MRI and ¹⁸F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. Eur J Radiol. 83:1169–1176. 2014. View Article : Google Scholar : PubMed/NCBI